- Pyrrolopyrazole derivative, preparation method and medical application thereof
-
The invention relates to pyrrolopyrazole derivative, a preparation method and application thereof in medicines. Specifically, the invention relates to a new pyrrolopyrazole derivative as shown in a general formula (I), a preparation method and application of the pyrrolopyrazole derivative or a pharmaceutical composition containing the pyrrolopyrazole derivative as a therapeutic agent, particularlyas a gastric acid secretion inhibitor and potassium-competitive acid blockers (P-CABs) in biological medicines. Specifically, the substituents (R1, R2, R3 and R4) in the general formula (I) are the same as the definitions in the specification.
- -
-
Paragraph 0104-0105
(2021/02/24)
-
- Pyrrolopyrazole derivatives and preparation method thereof, and application of pyrrolopyrazole derivatives in medicines
-
The invention relates to pyrrolopyrazole derivatives and a preparation method thereof, and application of the pyrrolopyrazole derivatives in medicines. Specifically, the invention relates to novel pyrrolopyrazole derivatives as shown in a general formula (I) in the specification, the preparation method of the pyrrolopyrazole derivatives and application of the pyrrolopyrazole derivatives or pharmaceutical compositions containing the pyrrolopyrazole derivatives as therapeutic agents, particularly as gastric acid secretion inhibitors and potassium ion competitive acid blockers (P-CABs) in biological medicines. All the substituents (R1, R2, R3 and R4) in the general formula (I) are as defined in the specification.
- -
-
Paragraph 0110-0111
(2021/03/13)
-
- SMALL MOLECULE AUTOPHAGY INDUCERS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES
-
Disclosed herein are compounds and methods for treating cancer and neurodegenerative diseases. In some examples, the compounds increase autophagy.
- -
-
-
- TYK2 INHIBITORS AND USES THEREOF
-
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
- -
-
Paragraph 00558
(2020/09/27)
-
- Pyrrolopyrazole derivative and preparation method thereof, and applications of pyrrolopyrazole derivative in medicine
-
The present invention relates to a pyrrolopyrazole derivative and a preparation method thereof, and applications of the pyrrolopyrazole derivative in medicine, particularly to a class of new pyrrolopyrazole derivatives represented by a general formula (I), and a preparation method thereof, and uses of the pyrrolopyrazole derivatives or pharmaceutical compositions containing the pyrrolopyrazole derivatives as treating agents, particularly as gastric acid secretion inhibitors and potassium ion competitive acid blockers (P-CABs) in biomedicine, wherein various substituents (R, R and R) and the groups (X, Y and Z) in the formula (I) are defined in the specification.
- -
-
Paragraph 0079
(2019/09/14)
-
- HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE
-
The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
- -
-
Paragraph 0346; 0348
(2016/02/18)
-
- SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
-
The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
- -
-
Paragraph 01427; 01428
(2015/04/28)
-
- ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
-
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The inventi
- -
-
Paragraph 0298; 0299; 0314
(2014/03/25)
-
- 8-Substituted isoquinoline derivative and the use thereof
-
The present invention relates to a compound represented by the following formula (1): wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.
- -
-
Page/Page column 119
(2010/11/03)
-
- BENZYLPIPERIZINE COMPOUND
-
Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a met
- -
-
Page/Page column 13; 14
(2010/05/13)
-
- Quinolinone derivaties and uses thereof
-
The invention provides compounds of the formula: and pharmaceutically acceptable salts or prodrugs thereof, wherein m, p, q, r, A, E, X, Y, R1, R4, R5, R6, R7, R8, R9 and are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.
- -
-
Page/Page column 21
(2008/06/13)
-
- NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS
-
The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4. The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4.
- -
-
-
- Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders
-
Sulfinyl and sulfonyl substituted 3-benzazepine compounds are useful in treating gastrointestinal motility disorders and emesis. A particular compound of this invention is 7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine.
- -
-
-
- Sulfinyl and sulfonyl substituted 3-benzazepines
-
Sulfinyl and sulfonyl substituted 3-benzazepine compounds are useful in treating gastrointestinal motility disorders. A particular compound of this invention is 8-hydroxy-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine.
- -
-
-
